Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

Nature Biotechnology

Volumn 31, Issue 1, 2013, Pages 71-75

  Kloss, Christopher C ^a,b   Condomines, Maud ^a   Cartellieri, Marc ^c   Bachmann, Michael ^c,d   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN RECEPTORS; ANTIGEN RECOGNITION; HEALTHY TISSUES; PROSTATE TUMOR; SIDE EFFECT; T CELLS; T-CELL RECEPTORS; TRANSDUCING;

ANTIGEN-ANTIBODY REACTIONS; CELL MEMBRANES; CYTOLOGY; TUMORS;

ANTIGENS;

CHIMERIC ANTIGEN RECEPTOR; CHIMERIC COSTIMULATORY RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CELL ENGINEERING; COMBINATORIAL LIBRARY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIGENS; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 84872196489     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2459     Document Type: Article

References (30)

1. Sadelain, M., Riviere, I. & Brentjens, R. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 3, 35-45 (2003 (Pubitemid 37328885)
2. Ho, W.Y., Blattman, J.N., Dossett, M.L., Yee, C. & Greenberg, P.D. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3, 431-437 (2003 (Pubitemid 38340289)
3. Sadelain, M., Brentjens, R. & Riviere, I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21, 215-223 (2009
4. Robbins, P.F. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29, 917-924 (2011
5. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73 (2011
6. Brentjens, R.J. et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828 (2011
7. Kochenderfer, J.N. et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720 (2012
8. Lamers, C.H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20-e22 (2006
9. Morgan, R.A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851 (2010
10. Krause, A. et al. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. 188, 619-626 (1998 (Pubitemid 28387925)
11. Duong, C.P., Westwood, J.A., Berry, L.J., Darcy, P.K. & Kershaw, M.H. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy 3, 33-48 (2011
12. Wilkie, S. et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J. Clin. Immunol. 1059-1070 (2012
13. Brentjens, R.J. et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 9, 279-286 (2003 (Pubitemid 36362782)
14. Maher, J., Brentjens, R.J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002 (Pubitemid 34044918)
15. Watts, T.H. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68 (2005 (Pubitemid 40563164)
16. Stephan, M.T. et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat. Med. 13, 1440-1449 (2007 (Pubitemid 350224246)
17. Carpenito, C. et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360-3365 (2009
18. Tammana, S. et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene Ther. 21, 75-86 (2010
19. Wang, J. et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum. Gene Ther. 18, 712-725 (2007 (Pubitemid 47378068)
20. Zhong, X.S., Matsushita, M., Plotkin, J., Riviere, I. & Sadelain, M. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 18, 413-420 (2010
21. Liao, W., Lin, J.X. & Leonard, W.J. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr. Opin. Immunol. 23, 598-604 (2011
22. Shin, S.M. et al. 4-1BB triggers IL-13 production from T cells to limit the polarized, Th1-mediated inflammation. J. Leukoc. Biol. 81, 1455-1465 (2007 (Pubitemid 46827968)
23. Schwartz, R.H. T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003 (Pubitemid 37174534)
24. Saeki, N., Gu, J., Yoshida, T. & Wu, X. Prostate stem cell antigen: a Jekyll and Hyde molecule? Clin. Cancer Res. 16, 3533-3538 (2010
25. Lam, J.S. et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin. Cancer Res. 11, 2591-2596 (2005 (Pubitemid 40569458)
26. Silver, D.A., Pellicer, I., Fair, W.R., Heston, W.D. & Cordon-Cardo, C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81-85 (1997 (Pubitemid 27079448)
27. Liu, J.C. et al. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERalpha- breast cancer. Proc. Natl. Acad. Sci. USA 109, 5832-5837 (2012
28. Meyer, M.J. et al. CD44posCD49fhiCD133/2hi defines xenograft-initiating cells in estrogen receptor-negative breast cancer. Cancer Res. 70, 4624-4633 (2010
29. Shih, I.-M. & Davidson, B. Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol. 5, 1641-1657 (2009
30. Strauss, R. et al. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. PLoS ONE 6, e16186 (2011)